Ablynx NV said that fresh data from a trial of its anti-tumour necrosis factor-alpha antibody for rheumatoid arthritis, ozoralizumab (ATN-103), has shown some promising results, at least one of which was unexpected. ---Subscribe to MedNous to access this article--- Company News Clinical Research
